{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-038742","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.319799+00:00","generated_at":"2026-05-24T20:33:25.215883+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025","bullets":["Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.","Top-line results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in CRS expected in Q2 2025.","Positive post-hoc data from ENLIGHTEN 1 extension in polyp cohort; FDA alignment on registration path for CRSwNP.","Planned reverse stock split to maintain Nasdaq listing; requires shareholder approval in Q2 2025.","R&D expenses decreased to $43.8M from $48.0M due to trial completions and workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-038742","json":"https://secwatch.observer/filing/0000950170-25-038742.json","markdown":"https://secwatch.observer/filing/0000950170-25-038742.md","text":"https://secwatch.observer/filing/0000950170-25-038742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/0000950170-25-038742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/lyra-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T20:33:25.215883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}